Shares of Lannett Company Inc. /zigman2/quotes/205623272/composite LCI -2.38% gained 0.2% after the company said it will cut 80 positions, about 8.5% of its total workforce, over concerns that its generic fluphenazine product will face competition from Amneal Pharmaceuticals Inc. /zigman2/quotes/209301288/composite AMRX -3.43% , which last week received a Food and Drug Administration approval for a generic form of the antipsychotic. Amneal said last week that annual U.S. sales of fluphenazine in the U.S. are $143 million. "LCI's dominance of the generic fluphenazine market, a key high margin driver and LCI's largest product in the wake of the loss of levothyroxine, ended yesterday with Amneal's entrance," Raymond James analyst Elliot Wilbur told investors on Friday. "Though competition was 'expected,' it is always hoped to happen later rather than sooner." The job losses will be at Lannett's Seymour, Indiana plant. Consolidating research & development in one location in Philadelphia is expected to save the company $15 million annually. Lannett's stock is down 34.9% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.80% has declined 1.4%.